On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418/AVZO-1418 globally, excluding Greater China. DB-1418/AVZO-1418 is an EGFR/HER3 bispecific antibody-drug conjugate (ADC) developed by Duality Bio.
Agreement Details
The licensing agreement grants Avenzo the exclusive rights to further develop and commercialize DB-1418/AVZO-1418 outside Greater China. This collaboration aims to leverage Avenzo’s expertise in drug development and commercialization to bring the potential benefits of DB-1418/AVZO-1418 to patients worldwide.-Fineline Info & Tech
